A detailed history of Gsa Capital Partners LLP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 8,682 shares of NBIX stock, worth $1.09 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
8,682
Previous 1,604 441.27%
Holding current value
$1.09 Million
Previous $221,000 352.49%
% of portfolio
0.08%
Previous 0.02%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$114.58 - $153.15 $810,997 - $1.08 Million
7,078 Added 441.27%
8,682 $1 Million
Q2 2024

Aug 15, 2024

BUY
$130.86 - $143.19 $209,899 - $229,676
1,604 New
1,604 $221,000
Q3 2023

Nov 15, 2023

SELL
$94.02 - $117.1 $45,317 - $56,442
-482 Reduced 19.71%
1,964 $220,000
Q2 2023

Aug 14, 2023

BUY
$89.53 - $104.87 $218,990 - $256,512
2,446 New
2,446 $230,000
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $894,953 - $1.07 Million
8,386 Added 220.51%
12,189 $1.46 Million
Q3 2022

Nov 14, 2022

SELL
$92.03 - $107.81 $121,755 - $142,632
-1,323 Reduced 25.81%
3,803 $404,000
Q2 2022

Aug 09, 2022

BUY
$75.79 - $100.07 $388,499 - $512,958
5,126 New
5,126 $500,000
Q4 2021

Feb 14, 2022

SELL
$79.65 - $106.22 $389,488 - $519,415
-4,890 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $421,420 - $484,256
4,890 New
4,890 $469,000
Q4 2020

Feb 03, 2021

SELL
$86.91 - $108.33 $615,409 - $767,084
-7,081 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$96.16 - $135.15 $520,706 - $731,837
5,415 Added 325.03%
7,081 $681,000
Q2 2020

Aug 11, 2020

BUY
$85.09 - $130.36 $141,759 - $217,179
1,666 New
1,666 $203,000
Q1 2020

May 12, 2020

SELL
$75.11 - $113.76 $1.09 Million - $1.66 Million
-14,569 Closed
0 $0
Q4 2019

Feb 12, 2020

BUY
$86.8 - $118.57 $819,392 - $1.12 Million
9,440 Added 184.05%
14,569 $1.57 Million
Q3 2019

Nov 12, 2019

SELL
$83.82 - $101.5 $383,141 - $463,956
-4,571 Reduced 47.12%
5,129 $462,000
Q2 2019

Aug 06, 2019

BUY
$72.24 - $91.27 $202,272 - $255,556
2,800 Added 40.58%
9,700 $819,000
Q1 2019

May 15, 2019

SELL
$69.31 - $91.53 $242,585 - $320,355
-3,500 Reduced 33.65%
6,900 $608,000
Q4 2018

Feb 12, 2019

BUY
$68.32 - $124.36 $379,995 - $691,690
5,562 Added 114.96%
10,400 $743,000
Q3 2018

Nov 13, 2018

BUY
$98.88 - $125.85 $478,381 - $608,862
4,838 New
4,838 $595,000
Q2 2018

Aug 09, 2018

SELL
$75.3 - $105.99 $183,054 - $257,661
-2,431 Closed
0 $0
Q1 2018

May 11, 2018

BUY
$75.88 - $92.43 $184,464 - $224,697
2,431 New
2,431 $202,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.